Cases & Deals

Sumitomo Dainippon Pharma concludes joint development and license agreement with SanBio for North America for SB623

Clients Sumitomo Dainippon Pharma Co., Ltd.

Jones Day advised Sumitomo Dainippon Pharma Co., Ltd. in a joint development and license agreement for exclusive marketing rights in the U.S. and Canada for SB623, a cell therapy for the treatment of patients with chronic stroke discovered and currently under development by SanBio Co., Ltd.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.